Benzinga | Oct 21, 2021 12:12PM EDT

Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $440

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Overweight and lowers the price target from $447 to $440.